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from the knee joints, we found an increase in collagen type
II degradation of 230% (p=0.07) on day 7, 300% (p=0.04) on day
14, and 240% (p=0.04) on day 28 in ACLT-operated knee joints
compared to sham-operated knee joints (see figure).
Conclusions: In a relative small sample size we demonstrated
that collagen type II degradation fragments extracted from joints
provide a useful surrogate marker for evaluating the disease
status of the entire joint. This approach may save essential time
in research models, compared to that of traditional histology
techniques, and provides information for the entire joint com-
pared to that of smaller regions of interests normally assessed
by histopathology. As collagen type II degradation fragments
are generated by MMPs, this approach may provide information
on pathologically MMP activity in the joint. We propose that this
technique may be used in various OA models and mouse genetic
phenotypes to assess joint disease status, and thereby provide
important information on pathology and efficacy of various po-
tential treatments for OA.
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PHARMACODYNAMIC MODULATION OF BONE-DERIVED
AND CARTILAGE-DERIVED COLLAGEN BIOMARKERS IN
THE OVARIECTOMIZED RAT MODEL
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Purpose: To understand how estrogen [E2] treatment, cathepsin
K [cat K] inhibition or matrix metalloproteinase [MMP] inhibition,
modulate markers of type I and type II collagen turnover in the
rat ovariectomy (ovx) model.
Methods: Six month old, skeletally mature female Sprague Daw-
ley rats were subject to ovx (n=48) or sham (n=8) surgery. Two
days later ("baseline"), the ovariectomized animals were random-
ized into the following groups (n=8/group except for ovx/vehicle:
n=16): Sham/vehicle, Ovx/vehicle, Ovx/E2 (17-α-estradiol @ 0.1
mg/kg po qd), Ovx/cat K inhibitor (CRA-013783 @ 50 mg/kg po
bid), Ovx/cat K inhibitor (CRA-013783 @ 50 mg/kg po bid dos-
ing: week 2 - week 4 only), Ovx/MMP inhibitor (RS-130830 @
50 mg/kg bid po). Urine (overnight) and plasma were collected
from each animal at study termination (4 weeks). Urine CTX-II
(uCTX-II: competition ELISA), plasma CTX-II (pCTX-II: sandwich
ELISA) and urine CTX-I (uCTX-I: competition ELISA) were all
assayed according to the manufacturers (Nordic Biosciences) in-
structions. Urine NET2C (uNET2C) was measured in-house via
immunoaffinity mass spectrometry. The data for each biomarker
were first Box-Cox transformed in order to comply with standard
statistical assumptions. Comparisons of means were performed
on the transformed data using Dunnett’s test to determine groups
statistically different from the ovx/vehicle group. Significance was
set at P<0.05. Type II collagen protein expression in femora
from 6 month intact female rats was determined via both western
and mass spectral analysis of bone extracts (metaphysis and
diaphysis). Type II collagen mRNA was determined via TaqMan
analysis of mRNA extracted from similar bone samples.
Results: In comparison to sham-operated animals, ovx in-
duced significant increases in the concentrations of all colla-
gen biomarkers measured in the study. uCTX-I concentration
was not affected by administration of the MMP inhibitor, but
was significantly reduced by E2 treatment and both cat K in-
hibitor dosing regimes. uCTX-II levels were significantly reduced
in each compound treated group. In contrast, although pCTX-II
was significantly decreased by estradiol treatment, it was not
lowered by the MMP inhibitor. pCTX-II levels were actually ele-
vated in both groups treated with the cat K inhibitor compared
to the ovx/vehicle group. uNET2C concentration was reduced by
E2 treatment but slightly increased in the cat K treated animals.
The MMP inhibitor reduced uNET2C levels; however, this did not
reach statistical significance.
Correlations between pCTX-II and uCTX-II (r=0.01), uNET2C
and uCTX-I (r=0.18), and between uNET2C and uCTX-II (r=0.03)
were uniformly absent. In contrast, uCTX-II and uCTX-I were
highly correlated (r=0.84) while pCTX-II and uNET2C also exhib-
ited reasonable correlation (r=0.52).
Type II collagen expression was confirmed at both the mRNA
and protein levels in samples of mature rat bone.
Conclusions: The poor correlation between uCTX-II and pCTX-
II implies that the two assays are measuring different molecular
species that are produced and/or processed via different mech-
anisms. In contrast, the high correlation between uCTX-I and
uCTX-II suggests that the production of these two collagen epi-
topes is mechanistically linked. The expression of type II collagen
in bone, plus the pharmacodynamic profiles of pCTX-II, uCTX-II
and uCTX-I suggest that in the rat ovx model, uCTX-II is pri-
marily bone derived whereas pCTX-II is cartilage-derived. These
data support the use of selective estrogen receptor modulators
for reducing cartilage as well as bone loss in estrogen deficient
states (e.g. menopause).
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Purpose: Osteoarthritis (OA) is known to occur naturally in both
the rhesus and cynomolgus macaque and develops anywhere
between 5 to 15 years of age. The structural, chemical and
biochemical changes seen in monkeys with OA closely resemble
the features of OA in humans. There is a great need to identify
and develop biomarkers for OA. The purpose of this study was
to evaluate the effect of age on the cartilage biomarkers of
young and old cynomolgus macaques. In addition, we have also
evaluated the effects of ovariectomy on these biomarkers.
Methods: Two sets of monkeys were used; the first with a mean
age of 4.2 years (SEM ± 0.3 years) and the second group with
a mean age of 10.9 years (SEM ± 0.5 years). The cartilage
degradation markers, serum and urinary C-telopeptide of colla-
gen type II (CTxII) and serum Cartilage Oligomeric Matrix Protein
(COMP) as well as the serum cartilage formation markers, ag-
grecan chondroitin sulfate 846 epitope (CS846) and Procollagen
II C-Propeptide (CPII) were evaluated in both groups of monkeys
prior to and following medical ovariectomy (OVX). Blood was
collected three times (separated by at least two weeks) prior to
induction of OVX. Medical OVX was induced with monthly injec-
tions of the GnRH agonist, Lupron, and additional blood draws
were taken for biomarker analysis. Parameters for the groups
were compared using the Student’s ttest with significance set at
p ≤ 0.05.
Results: Prior to medical ovariectomy, urinary and serum CTxII
levels were 16- and 17-fold higher, respectively, in the young
versus older monkeys (42.2 to 2.7 ng/mg of creatinine, respec-
tively for urine and 63.7 and 3.7 pg/ml for serum). COMP levels
were also significantly higher in younger monkeys than the older
group (3.1 vs. 2.1 U/L) whereas serum CS846 levels were not
different between the two age groups. CPII levels, however, were
significantly higher in the older than younger monkeys (745 vs.
605 ng/mL).
Biomarkers were also evaluated following medical ovariectomy
using Lupron. Urinary CTxII levels were significantly elevated by
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week 16 post the first Lupron treatment in the older monkeys
but no increase was observed in the younger monkeys. No
differences in serum CTxII due to OVX were noted in either group.
However in the younger monkeys, Lupron treatment resulted in
increases in COMP and CPII. COMP was significantly increased
compared to pre Lupron treatment two weeks after the first
Lupron injection and remained significantly elevated through
week 12. CPII in the younger monkeys did not increase until 12
weeks after the first Lupron injection. In the older monkeys, no
differences in COMP and CPII due to OVX were noted.
Conclusions: In summary, this data demonstrated that ani-
mal age affects cartilage biomarker levels. Secondly, medical
ovariectomy was able to cause increases in cartilage turnover
and the response varied depending upon the age of the ani-
mal. These data suggest some of these biomarkers could be
useful in monkeys to monitor the response to experimental OA
drugs.
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Purpose: Aurothiomalate is used in the treatment of arthri-
tis. Prostaglandin E2 (PGE2) production is increased in various
forms of arthritis. The key enzymes in inflammatory PGE2 syn-
thesis are inducible cyclooxygenase-2 (COX-2) and inducible
microsomal prostaglandin E synthase-1 (mPGES-1). Two other
forms of prostaglandin E synthase (PGES), microsomal PGES-2
(mPGES-2) and cytosolic PGES (cPGES) are ubiquitously ex-
pressed. In the present study, we investigated the effects of
aurothiomalate on interleukin-1β (IL-1β) -induced COX-2 and
PGES expression and subsequent PGE2 production in immortal-
ized murine H4 chondrocytes and in human osteoarthritic (OA)
cartilage.
Methods: Cartilage tissue was obtained from the leftover pieces
of total knee replacement surgery from patients with OA. PGE2
production was measured by RIA, protein expression was mea-
sured by Western blot and mRNA expression was measured by
quantitative PCR.
Results: Aurothiomalate inhibited IL-1β -induced PGE2 produc-
tion in chondrocytes and in human cartilage. Aurothiomalate
inhibited also COX-2 and mPGES-1 expression but did not have
an effect on mPGES-2 or cPGES. Aurothiomalate enhanced
COX-2 mRNA degradation in IL-1β -treated chondrocytes. This
mechanism may well explain the inhibitory effect of aurothioma-
late on COX-2 expression.
Conclusions: Aurothiomalate suppressed IL-1β -induced COX-
2 and mPGES-1 expression in chondrocytes and in human
OA cartilage. The results suggest a novel anti-inflammatory
mechanism for aurothiomalate.
P92 – Table 1. Serum levels (mean±SD) of C2C, Coll2-1 and Coll2-1NO2 biomarkers in wild-type (WT) and biglycan/fibromodulin double-deficient mice (DKO).
C2C (ng/ml) Coll2-1 (nM) Coll2-1NO2 (nM)
Age (days) WT DKO p WT DKO p WT DKO p
49 / / / 200±30 222±31 0.06 1.38±0.22 2.22±0.42 0.000
66 32±16 52±14 0.001 / / / / / /
81 / / / 245±40 281±61 0.06 1.90±0.38 1.63±0.32 0.053
95 / / / 305±32 362±60 0.005 1.81±0.54 2.89±0.67 0.000
141 30±16 50±26 0.03 264±24 303±35 0.008 2.37±0.24 2.04±0.41 0.027
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Purpose: Compared to wild-type mice (WT), biglycan/fibromod-
ulin double deficient mice (DKO) develop premature and severe
knee OA. In this study, we aimed at comparing 1) type II collagen
catabolism between the 2 genotypes and 2) the usefulness of
C2C, Coll2-1 and Coll2-1NO2 biomarkers to evaluate collagen
catabolism in an animal model of osteoarthritis.
Methods: Serum levels of the type II collagen biomarkers C2C,
Coll2-1 and Coll2-1NO2 were determined in 15 WT and 15 DKO
at the age of 66 and 141 days for C2C and at the age of 49, 81, 95
and 141 days for Coll2-1 and Coll2-1NO2. Mice were sacrificed
at day 141. C2C, Coll2-1 and Coll2-1NO2 immunohistochemistry
was performed on coronal histological sections of knee joints.
Results: The mean serum concentrations of Coll2-1 and C2C
were significantly higher in DKO than in WT at all time points
(see Table 1). The DKO/WT ratios for these 2 biomarkers re-
mained approximately constant with time and were ∼1.63 for
C2C and ∼1.15 for coll2.1. In contrast, Coll2-1NO2 displayed
cyclic variations with a DKO/WT ratio ∼1.60 at day 49 and 95 but
=0.86 at intermediate time points (day 81 and 141) (see Table).
In both genotypes, immunostainings with Coll2-1, Coll2-1NO2
and C2C labelled some fibroblasts in tendons and menisci as
well as the chondrocytes above the tidemark in articular cartilage
whereas chondrocytes in the growth plate remained unstained.
For the 3 biomarkers, extracellular stainings was limited to fi-
brocartilage areas in tendons and menisci from both genotypes
and to some of the focal lesions of the biglycan/fibromodulin
deficient cartilage. No extracellular staining was observed in WT
cartilage.
Conclusions: Our study demonstrates a higher type II collagen
catabolism in the biglycan/fibromodulin double-deficient mouse.
The different DKO/WT ratios observed with C2C, Coll2-1 and
Coll2-1NO2 suggest that these 3 serum biomarkers give com-
plementary rather than redundant information on type II collagen
catabolism. C2C and Coll2-1 are useful to directly monitor col-
lagen degradation in animal models of osteoarthritis whereas
Coll2-1NO2 is less suitable as it requires the additional presence
of oxidative stress.
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Purpose: Osteoarthritis is considered to have heterogeneous
metabolism, involving all joint tissues. However, it is not known
in whom the disease will progress. The latter is characterized
